We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Quince Therapeutics Inc | NASDAQ:QNCX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -2.91% | 1.00 | 1.00 | 1.13 | 1.08 | 0.98 | 1.01 | 120,833 | 00:12:34 |
As filed with the Securities and Exchange Commission on March 1, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Cortexyme, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 90-1024039 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
269 East Grand Ave.
South San Francisco, CA 94080
(415) 910-5717
(Address of Principal Executive Offices) (Zip Code)
Cortexyme, Inc. 2019 Equity Incentive Plan
Cortexyme, Inc. 2019 Employee Stock Purchase Plan
(Full title of the plans)
Casey C. Lynch
Chief Executive Officer
Cortexyme, Inc.
269 East Grand Ave.
South San Francisco, CA 94080
(415) 910-5717
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Please send copies of all communications to:
Gordon K. Ho
Cooley LLP
3175 Hanover Street
Palo Alto, California 94304
(650) 843-5000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
||||||||
Title of Securities to be Registered |
Amount to be Registered (1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering Price |
Amount of Registration Fee |
||||
Common stock, $0.001 par value per share |
||||||||
- Reserved for future issuance under the 2019 Equity Incentive Plan |
1,181,729 (2) | $31.49 (3) | $37,212,646.21 | $4,060.00 | ||||
- Reserved for future issuance the 2019 Employee Stock Purchase Plan |
295,432 (4) | $26.77 (5) | $7,908,714.64 | $863.00 | ||||
TOTAL |
1,477,161 | $45,121,360.85 | $4,923.00 | |||||
|
||||||||
|
(1) |
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this registration statement on Form S-8 (Registration Statement) shall also cover any additional shares of the common stock of Cortexyme, Inc. (the Registrant) that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrants receipt of consideration that results in an increase in the number of the outstanding shares of the Registrants common stock. |
(2) |
Represents 1,181,729 additional shares of the Registrants common stock that were automatically added to the shares authorized for issuance under the Registrants 2019 Equity Incentive Plan (the 2019 Plan) on January 1, 2021, pursuant to an annual evergreen increase provision contained in the 2019 ESPP. |
(3) |
Estimated in accordance with Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $31.49 was computed by averaging the high and low prices of a share of the Registrants common stock as reported on The Nasdaq Global Select Market on February 23, 2021. |
(4) |
Represents 295,432 additional shares of the Registrants common stock that were automatically added to the shares authorized for issuance under the Registrants 2019 Employee Stock Purchase Plan (the 2019 ESPP) on January 1, 2021, pursuant to an annual evergreen increase provision contained in the 2019 ESPP. |
(5) |
Estimated in accordance with Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee. The proposed maximum offering price per share is equal to 85% of $31.49, which was computed by averaging the high and low prices of a share of the Registrants common stock as reported on The Nasdaq Global Select Market on February 23, 2021. Under the 2019 ESPP, the purchase price of a share of common stock is equal to 85% of the fair market value of the Registrants common stock on the offering date or the purchase date, whichever is less. |
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the Commission) to register 1,181,729 additional shares of common stock under the 2019 Plan and 295,432 additional shares of common stock under the 2019 ESPP pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans. This Registration Statement hereby incorporates by reference the contents of the Registrants registration statement on Form S-8 filed with the Commission on May 9, 2019 (Registration No. 333-231307) and on March 16, 2020 (File No. 333-237199).
PART II
ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE
The following documents filed by Registrant with the Commission are incorporated by reference into this Registration Statement:
(a) |
The Registrants Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Commission on March 1, 2021; |
(b) |
The Registrants Current Reports on Form 8-K filed with the Commission on January 25, 2021, January 26, 2021 (only with respect to Item 8.01), February 10, 2021 and February 16, 2021; and |
(c) |
The description of the Registrants Common Stock contained in the registration statement on Form 8-A registering the Registrants Common Stock under Section 12 of the Exchange Act filed with the Commission on May 1, 2019, including any amendments or reports filed for purposes of updating such description. |
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item 8. Exhibits.
The following exhibits are filed herewith:
Exhibit Number |
Exhibit Description | Incorporated by Reference | ||||||||||||||
Form | File No. | Exhibit | Filing Date |
Filed Herewith |
||||||||||||
4.1 | Amended and Restated Certificate of Incorporation | 8-K | 001-38890 | 3.1 | 5/13/2019 | |||||||||||
4.2 | Amended and Restated Bylaws | 8-K | 001-38890 | 3.2 | 5/13/2019 | |||||||||||
4.3 | Specimen Stock Certificate | S-1/A | 333-230853 | 4.1 | 4/29/2019 | |||||||||||
5.1 | Opinion of Cooley LLP | X | ||||||||||||||
23.1 | Consent of Cooley LLP (included in Exhibit 5.1) | X | ||||||||||||||
23.2 | Consent of Independent Registered Public Accounting Firm | X | ||||||||||||||
24.1 | Power of Attorney (included on the signature page of this Registration Statement) | X | ||||||||||||||
99.1 | 2019 Equity Incentive Plan, and forms of stock award agreements thereunder | S-1/A | 333-230853 | 10.4 | 4/29/2019 | |||||||||||
99.2 | 2019 Employee Stock Purchase Plan | S-1/A | 333-230853 | 10.5 | 4/29/2019 |
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on March 1, 2021.
CORTEXYME, INC. |
/s/ Casey C. Lynch |
Casey C. Lynch |
President, Chief Executive Officer and Chairman |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Casey C. Lynch, Christopher Lowe and Caryn McDowell, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:
Name | Title | Date | ||
/s/ Casey C. Lynch |
President, Chief Executive Officer and Chairman of our Board of Directors |
March 1, 2021 | ||
Casey C. Lynch | (Principal Executive Officer) | |||
/s/ Christopher Lowe |
Chief Operating Officer and Chief Financial Officer (Principal Financial Officer) |
March 1, 2021 | ||
Christopher Lowe | ||||
/s/ Ted Monohon |
Chief Accounting Officer and Vice President, Finance | March 1, 2021 | ||
Ted Monohon | (Principal Accounting Officer) | |||
/s/ Stephen S. Dominy |
Director | March 1, 2021 | ||
Stephen S. Dominy | ||||
/s/ David A. Lamond |
Director | March 1, 2021 | ||
David A. Lamond | ||||
/s/ Margaret McLoughlin, Ph.D. |
Director | March 1, 2021 | ||
Margaret McLoughlin, Ph.D. | ||||
/s/ Una Ryan, OBE, Ph.D. |
Director | March 1, 2021 | ||
Una Ryan, OBE, Ph.D. | ||||
/s/ Christopher J. Senner |
Director | March 1, 2021 | ||
Christopher J. Senner | ||||
/s/ Kevin Young, CBE |
Director | March 1, 2021 | ||
Kevin Young, CBE |
1 Year Quince Therapeutics Chart |
1 Month Quince Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions